A decreasing trend in efficacy at higher doses was observed, an effect that may be explained by negative feedback regulation inherent to growth factor systems [ [77] , [78] , [79] , [80] ].
← all excerpts
Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease.
1
—
—